I am writing to you to request your continued support for Nicox by voting in the upcoming Nicox Ordinary and Extraordinary General Meetings to be convened on May 3, 2018.
2017 was a pivotal year for Nicox, marked by the approval of two of our assets by the U.S. Food and Drug Administration. VYZULTA® licensed worldwide to Bausch + Lomb, was approved for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and then subsequently commercialized in the U.S. in December 2017. ZERVIATETM, partnered with Eyevance Pharmaceuticals for the U.S. market, was approved for the treatment of ocular itching associated with allergic conjunctivitis, and a launch is planned for the upcoming fall 2018 allergy season.
As we look ahead to 2018, we expect to recognize the first sales of both VYZULTA and ZERVIATE in the U.S. market, and thus, the first recurrent revenues for Nicox through the royalties due to us from our partners. In parallel, we are diligently working to advance our two pipeline assets, NCX 470 for IOP lowering in patients with open angle glaucoma or ocular hypertension and NCX 4251 for the treatment of blepharitis, towards the initiation of proof-of-concept Phase 2 clinical studies. With these two product candidates, both of which target ocular indications with high unmet need, we believe we are well positioned to rapidly expand our footprint as a leading R&D player in ophthalmology.
We are working hard to ensure that the potential of both the approved products and our pipeline are fully understood and recognized by the international markets, and we are striving to unlock the full value of Nicox shares through both the sales of VYZULTA and ZERVIATE by our partners in the U.S., and the rapid advancement of our innovative ophthalmic pipeline. In order to achieve all of this, we need your support and your vote in the upcoming Ordinary and Extraordinary General Meetings is critically important.
For this purpose, a proxy form, the draft resolutions, a guide explaining how to vote, and several other documents pertaining to the General Meetings are enclosed. You may either vote by proxy, by internet or attend the General Meetings in person on May 3, 2018 at 2:00 pm CET in the offices of BuroClub – Drakkar 2 – Bât D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France. All the documents pertaining to the General Meetings are available on Nicox website www.nicox.com (‘Shareholder Meetings’ button on the home page).
Should you have any question on the voting process, please contact our Investor Relations team either by e-mail at email@example.com or by phone at +33 4 97 24 53 63.
With my best regards,
Chairman & Chief Executive Officer